Theme: Novel Insights in Therapeutic Strategies on COPD

COPD 2016
scientific program

Renowned Speakers

COPD 2016

ConferenceSeries Ltd invites participants from all over the world to attend, “3rd International Conference on Chronic Obstructive Pulmonary Disease” which is going to be held during July 11-12, 2016 at Brisbane, Australia. The theme of the conference is “Novel Insights in Therapeutic Strategies on COPD".  

COPD-2016 conference enables a common platform to the participants to discuss their research in order to establish a scientific network between the academia and industry leading to foster collaboration and to evaluate the emerging issues, technologies and innovations leading to explore new possibilities and improving the existing opportunities in the field of air way diseases. The gathering welcomes members from every driving university, clinical examination foundations and symptomatic organizations to share their exploration encounters on all parts of this quickly extending field and subsequently, giving a showcase of the most recent advanced procedures in the treatment of lung disorders.

Track 1 Lungs and its Functions; An Overview

The lungs are a pair of organs in the chest that are primarily responsible for the exchange of oxygen and carbon dioxide between the air and blood. The exchange of the air between the lungs and blood are through the arterial and venous system. Arteries and veins both carry and move blood throughout the body, but the process for each is very different. The lungs are a pair of cone-shaped organs made up of spongy, pinkish-grey tissue. They take up most of the space in the chest, or the thorax (the part of the body between the base of the neck and diaphragm). One main stem bronchus leads to the right lung and one to the left lung. In the lungs, the main stem bronchi divide into smaller bronchi and then into even smaller tubes called bronchioles. Bronchioles end in tiny air sacs called alveoli. Breathing becomes more challenging in chronic obstructive lung disease because more mucus and also infection is produced in the lungs. The bronchioles become inflamed and narrower in COPD patient.

Related Conference: 3rd Euro-Global Conference on Infectious Diseases September 5-6, 2016 Frankfurt, Germany; International Conference on Chest November 17-18, 2016 Dubai, UAE; 4th International Conference and Exhibition on Lung & Respiratory Care August 01-02, 2016 Manchester, UK; 2nd International Conference on Respiratory and Pulmonary Medicine October 17-19, 2016 Chicago, USA; 8th Health care Conference November 17-19, 2016 Dubai UAE; Pulmonology Conference: Sleep, Heart, and the Lungs May 6, 2016 Philadelphia, United States; 12th Annual Pulmonary, Critical Care and Sleep Medicine Conference May 5-6, 2016, Omaha, United States; 19th World Association for Bronchology and Interventional Pulmonology May 8-11, 2016 Rome, Italy; Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA; British Thoracic Society Summer Meeting June 23-24, 2016 York, UK

 Track 2 Causes of COPD

COPD is a disease that involves inflammation and thickening of the airways. It also involves destruction of the tissue of the lung where oxygen is exchanged. It is described by the Global Initiative for Chronic Obstructive Lung Disease as “a preventable and treatable disease…characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases. This progressive and relentless loss of lung function is caused by emphysema due to destruction of lung parenchyma with mycobacterial genetics. Smoking (long term smokers), Chronic Bronchitis, Inherited factors (genes) and by narrowing of small airways as a result of chronic inflammatory mediators and fibrosis and loss of elastic recoil. This results in progressive airflow limitation, air trapping, and progressive shortness of breath on exertion.

Related Conference: 3rd Euro-Global Conference on Infectious Diseases September 5-6, 2016 Frankfurt, Germany; 4th International Congress on Bacteriology and Infectious Diseases May 16-18, 2016 San Antonio, Texas, USA; 2nd World Congress on Infectious Diseases August 24 - 26, 2016 Philadelphia, Pennsylvania; 2nd International Conference on Respiratory and Pulmonary Medicine October 17-19, 2016 Chicago, USA; World Congress on Infection Prevention and Control November 28-29, 2016 Valencia, Spain; Austrian Society of Pneumology October 6-8, 2016 Vienna, Austria; European Society of MycoBacteriology July 3-6, 2016 Italy; British Thoracic Society Summer Meeting June 23-24, 2016 York, UK; International Convocation Centre COPD 10, June 29- July 1, 2016 Birmingham, UK; Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA

Track 3 Pathophysiology of COPD

The current paradigm for the pathogenesis of chronic obstructive pulmonary disease is that chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. Airspace inflammation appears to be different in susceptible smokers and Chronic Inflammation involves a predominance of inhaled irritants such as CD8+ T lymphocytes, neutrophils, and macrophages, B cells and macrophages to accumulate. When activated, these cells initiate an inflammatory cascade that triggers the release of inflammatory mediators such as tumour necrosis factor alpha (TNF-α), and leads   to   Structural changes.  Airway remodelling in COPD is a direct result of the inflammatory response associated with COPD and leads to narrowing of the airways. Three main factors contribute to this: peril bronchial fibrosis, build-up of scar tissue and Infection Control from damage to the airways and over-multiplication of the epithelial cells lining the airways. Parenchymal destruction is associated with loss of lung tissue elasticity and interstitial lung disease, which occurs as a result of destruction of the structures supporting and feeding the alveoli. This means that the small airways collapse during exhalation, impeding airflow, trapping air in the lungs and reducing lung capacity.

 Related Conference: 4th International Congress on Bacteriology and Infectious Diseases May 16-18, 2016 San Antonio, Texas, USA; 8th Health care Conference November 17-19, 2016 Dubai UAE; International Conference on Chest November 17-18, 2016 Dubai, UAE; 5th International Conference and Exhibition on Occupational Health & Safety June 06-07, 2016 Dallas, USA; 4th International Conference and Exhibition on Lung & Respiratory Care August 01-02, 2016 Manchester, UK; 12th Annual Pulmonary, Critical Care and Sleep Medicine Conference May 5-6, 2016, Omaha, United States; Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA; British Thoracic Society Summer Meeting June 23-24, 2016 York, UK; Austrian Society of Pneumology October 6-8, 2016 Vienna, Austria; International Convocation Centre COPD 10, June 29- July 1, 2016 Birmingham, UK

 

 Track 4 COPD and Co-Morbidities

Comorbidities such as cardiac disease, diabetes mellitus, hypertension, osteoporosis, and psychological disorders are commonly reported in patients with chronic obstructive pulmonary disease (COPD) but with great variability. Tobacco smoking is a risk factor for many of these comorbidities as well as for COPD, making it difficult to draw conclusions about the relationship between COPD and these comorbidities including Lung Cancer. Epidemiological studies and large clinical trials have helped us to understand the importance of comorbidities with interstitial lung disease; however recent large epidemiologic studies have confirmed the independent detrimental effects of these comorbidities on patients with COPD associated with Musculoskeletal System. Many of these comorbidities are now considered to be part of the commonly prevalent to Chronic Obstructive Pulmonary Disease. The common ground between most of these extra pulmonary manifestations is chronic systemic inflammation.

Related Conference: 2nd World Congress on Infectious Diseases August 24 - 26, 2016 Philadelphia, Pennsylvania, USA; World Congress on Infection Prevention and Control November 28-29, 2016 Valencia, Spain; International Conference on Chest November 17-18, 2016 Dubai, UAE; 5th International Conference and Exhibition on Occupational Health & Safety June 06-07, 2016 Dallas, Texas, USA; 8th Health care Conference November 17-19, 2016 Dubai UAE; Pulmonology Conference: Sleep, Heart, and the Lungs May 6, 2016 Philadelphia, United States; 19th World Association for Bronchology and Interventional Pulmonology May 8-11, 2016 Rome, Italy; Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA; European Society of MycoBacteriology July 3-6, 2016 Italy; Austrian Society of Pneumology October 6-8, 2016 Vienna, Austria

Track 5 Drugs Acting on COPD

Many treatments can help ease the symptoms and slow the progression of the illness. There are several paths for the treatment of chronic obstructive pulmonary disease. However, lifestyle changes and treatments can help you feel better, stay more active, and slow the progress of the disease. Health care provider may prescribe medications to control the symptoms of COPD like bronchodilators, anti-inflammatories, and antibiotics with targeted drug therapy. The main therapeutic options for the management of COPD are inhaled corticosteroids and bronchodilators. Inhaled corticosteroids significantly reduce inflammatory cells in the lungs made drug development research as well as systemic inflammatory markers such as C-reactive protein, compared with placebo with Internal Medicine. The goals of chronic obstructive pulmonary disease treatment include relieving symptoms, slowing the progress of the disease, preventing and treating complications, and improving overall health status. In patients with COPD bronchodilators improve lung function to some extent and relieve dyspnea. Within short-acting   bronchodilators, ipratropium is as effective as salbutamol (sympathomimetic agent) with fewer adverse effects. Presently, maintenance therapy is based on long-acting inhaled bronchodilators.

Related Conference: 2nd World Congress on Infectious Diseases August 24 - 26, 2016 Philadelphia, Pennsylvania, USA; 5th International Conference and Exhibition on Occupational Health & Safety June 06-07, 2016 Dallas, Texas, USA; 8th Health care Conference November 17-19, 2016 Dubai UAE; 3rd Euro-Global Conference on Infectious Diseases September 5-6, 2016 Frankfurt, Germany; 4th International Congress on Bacteriology and Infectious Diseases May 16-18, 2016 San Antonio, Texas, USA; International Convocation Centre COPD 10, June 29- July 1, 2016 Birmingham, UK; Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA; 12th Annual Pulmonary, Critical Care and Sleep Medicine Conference May 5-6, 2016, Omaha, United States; Pulmonology Conference: Sleep, Heart, and the Lungs May 6, 2016 Philadelphia, United States; European Society of MycoBacteriology July 3-6, 2016 Italy

Track 6 Clinical Evaluation of COPD

Assessment of patients with chronic obstructive pulmonary disease (COPD) is important to establish an accurate diagnosis, assist in making therapeutic decisions, measuring outcomes for clinical and research purposes. Assessment of patients with COPD for both clinical and research purposes should incorporate a variety of different outcomes. There are outcome measures that have been successfully incorporated in large clinical trials and the design and outcomes of these trials can be used to plan future clinical investigations in COPD. The most widely used current definitions of COPD are provided by two current clinical practice guidelines.

Related Conference: 3rd Euro-Global Conference on Infectious Diseases September 5-6, 2016 Frankfurt, Germany; 4th International Conference and Exhibition on Lung & Respiratory Care August 01-02, 2016 Manchester, UK; 2nd International Conference on Respiratory and Pulmonary Medicine October 17-19, 2016 Chicago, USA; International Conference on Chest November 17-18, 2016 Dubai, UAE; 8th Health care Conference November 17-19, 2016 Dubai UAE;  Austrian Society of Pneumology October 6-8, 2016 Vienna, Austria; European Society of MycoBacteriology July 3-6, 2016 Italy; British Thoracic Society Summer Meeting June 23-24, 2016 York, UK; International Convocation Centre COPD 10, June 29- July 1, 2016 Birmingham, UK; Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA

 Track 7 Diagnostics Techniques of COPD

Clinical history and physical examination should help to determine the possible cause and site of respiratory disease. The results of the history, physical examination, and chest x-ray often suggest what additional testing may be needed to determine what is causing the person's symptoms.  A test for lung disorders is done by measuring the lungs' capacity. Transthoracic fine needle aspirates of lung often are useful in the diagnosis of fungal pneumonia but have lower yields in the definitive diagnosis of solitary pulmonary lesions. Solitary pulmonary function masses often require transthoracic lung biopsy or surgical excision for definitive diagnosis with medical screening. Transthoracic ultrasonography is a sensitive diagnostic tool for pleural disease (eg, pleural effusion, pneumothorax) and for parenchymal lung disease when lesions are adjacent to the pleural surface.

Related Conference: 2nd World Congress on Infectious Diseases August 24 - 26, 2016 Philadelphia, Pennsylvania, USA; 4th International Conference and Exhibition on Lung & Respiratory Care August 01-02, 2016 Manchester, UK; 2nd International Conference on Respiratory and Pulmonary Medicine October 17-19, 2016 Chicago, USA; 8th Health care Conference November 17-19, 2016 Dubai UAE; 5th International Conference and Exhibition on Occupational Health & Safety June 06-07, 2016 Dallas, Texas, USA; Pulmonology Conference: Sleep, Heart, and the Lungs May 6, 2016 Philadelphia, United States; 19th World Association for Bronchology and Interventional Pulmonology May 8-11, 2016 Rome, Italy; Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA; European Society of MycoBacteriology July 3-6, 2016 Italy; International Convocation Centre COPD 10, June 29- July 1, 2016 Birmingham, UK;

  Track 8 Developments in COPD Management

The aim of the present study is to manage the impact of COPD on health status by Characterization of human lung tissues by advanced molecular, biochemical, microbiological, and histopathological methods. A better understanding of the cellular and molecular mechanisms that are involved in the underlying inflammatory and destructive processes has revealed several new targets for which drugs are now in development, and the prospects for finding new treatments are good. Research progress in COPD is hampered by a lack of fundamental knowledge regarding the pathology of this disease, particularly with regard to small airways. Changes with Chronic Obstructive Pulmonary Disease in the structure, cellular composition, chronic inflammatory status, and chemical milieu of the lung are poorly defined, as are the relationships of these changes to clinical manifestations of the disease. Characterization of lung tissues can now be performed with exquisite detail, using advanced methods of immunology. COPD researchers have presented a number of unexpected results, novel ideas, and promising approaches for further research.

Related Conference: World Congress on Infection Prevention and Control November 28-29, 2016 Valencia, Spain; 4th International Conference and Exhibition on Lung & Respiratory Care August 01-02, 2016 Manchester, UK; 2nd International Conference on Respiratory and Pulmonary Medicine October 17-19, 2016 Chicago, USA; 8th Health care Conference November 17-19, 2016 Dubai UAE; 3rd Euro-Global Conference on Infectious Diseases September 5-6, 2016 Frankfurt, Germany; 19th World Association for Bronchology and Interventional Pulmonology May 8-11, 2016 Rome, Italy;  Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA; British Thoracic Society Summer Meeting June 23-24, 2016 York, UK; Austrian Society of Pneumology October 6-8, 2016 Vienna, Austria; Pulmonology Conference: Sleep, Heart, and the Lungs May 6, 2016 Philadelphia, United States;

 

 Track 9 Advancement in Lung Surgeries

Surgery is needed to take biopsies (tissue samples) of the lung for diagnosis. Recent advances in optic/video systems and endoscopic operating instruments have made thoracoscopic easier and more accurate than 20 years ago. The operative mortality rate was low (1%) and the diagnostic accuracy high (99%). Thoracoscopy has been performed at an increasing frequency in recent years because of its expanded applications, especially in the areas of therapeutic or operative procedures such as carbon dioxide laser treatment of spontaneous pneumothorax or diffuse bullous emphysema and Lung volume reduction and also in the treatment of various airway diseases. Two common ways to do surgery on your lungs are thoracotomy and video-assisted thoracoscopic surgery (VATS). It involves passing a telescopic camera through small cuts in the chest to examine the lungs or pleura (linings of the lung) under video guidance and also associated with lung transplantation.

Related Conference: 2nd World Congress on Infectious Diseases August 24 - 26, 2016 Philadelphia, Pennsylvania, USA; 4th International Congress on Bacteriology and Infectious Diseases May 16-18, 2016 San Antonio, Texas, USA; World Congress on Infection Prevention and Control November 28-29, 2016 Valencia, Spain; 2nd International Conference on Respiratory and Pulmonary Medicine October 17-19, 2016 Chicago, USA; 8th Health care Conference November 17-19, 2016 Dubai UAE; European Society of MycoBacteriology July 3-6, 2016 Italy; International Convocation Centre COPD 10, June 29- July 1, 2016 Birmingham, UK; 19th World Association for Bronchology and Interventional Pulmonology May 8-11, 2016 Rome, Italy; Pulmonology Conference: Sleep, Heart, and the Lungs May 6, 2016 Philadelphia, United States, 12th Annual Pulmonary, Critical Care and Sleep Medicine Conference May 5-6, 2016, Omaha, United States;

 

 Track 10 Control Measures for Prevention of COPD

People with COPD have difficulty clearing their lungs of bacteria, dusts and other pollutants in the air. This makes them at risk for lung infections that may cause further damage to the lungs. Historically, acute toxicity was associated with occupational exposures to concentrations of soluble beryllium salts greater than 100 μg/m3. With the advent of industrial control measures to minimize air levels, acute pulmonary syndromes have virtually disappeared in respective to COPD. In addition to environmental exposure, Occupational epidemiology genetic predisposition with pulmonary critical care seems to have a major role in the development of CBD. A variant of the human leukocyte antigen (HLA-DPb1 [Glu69]) is found in 80% to 97% of patients with CBD and in only 30% of controls.

Related Conference: 3rd Euro-Global Conference on Infectious Diseases September 5-6, 2016 Frankfurt, Germany; 2nd World Congress on Infectious Diseases August 24 - 26, 2016 Philadelphia, Pennsylvania, USA; 2nd International Conference on Respiratory and Pulmonary Medicine October 17-19, 2016 Chicago, USA; 8th Health care Conference November 17-19, 2016 Dubai UAE; 5th International Conference and Exhibition on Occupational Health & Safety June 06-07, 2016 Dallas, USA; Pulmonary Hypertension Association International Conference June 17-19, 2016 Dallas, USA; European Society of MycoBacteriology July 3-6, 2016 Italy; Austrian Society of Pneumology October 6-8, 2016 Vienna, Austria; International Convocation Centre COPD 10, June 29- July 1, 2016 Birmingham, UK; 19th World Association for Bronchology and Interventional Pulmonology May 8-11, 2016 Rome, Italy;

 

 

 

 

 

 

 

 

 

ConferenceSeries invites all the participants from all over the world to attend “3rd International Conference on Chronic Obstructive Pulmonary Disease” during July 11-12, 2016 at Brisbane, Australia  which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

 

COPD 2016 will throw light on thought provoking topics and recent research in the field of lung related issues.COPD-2016 is a trending conference which brings together efficient academic scientists, super specialists, young researchers,  making a perfect platform to gain experience, and evaluate emerging technologies across the globe to discuss about recent advancements in COPD. Initiation of cross border coordination between scientists and institutions will be also facilitated.  International symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Chronic Obstructive Pulmonary Disease. OMICS International organizes a conference series of 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

 

Why to Attend???

COPD represents serious Lung-related health complications that have devastating impacts on people, public health, and economies. This disease is responsible for rising healthcare costs, lost productivity, and long-term disability. This conference will feature a global audience of scientific leaders, academia and respiratory professionals, who are going to discuss today’s emerging treatments and diagnostics. By bringing together the pulmonary community, presenting the latest developments, and identifying unmet treatment needs, COPD-2016 hopes to accelerate research and drug development in COPD, improving patient outcomes. It is designed to provide an educational forum that stimulates clinical, research, government and patient communities to create a coordinated and comprehensive approach for advancing the implementation of research, clinical care, care delivery coordination and other public health interventions critical to improved outcomes in COPD.

 

 Target Audience:

 ·         COPD Students, Scientists

·         COPD Researchers

·         COPD Faculty

·         Medical Colleges

·         COPD Associations and Societies

·         Business Entrepreneurs

·         Training Institutes

·         Manufacturing Medical Devices Companies

·         Pulmonary Medicine and surgery related Companies

Summary: COPD 2016 is to promote the health awareness which includes plenary speeches, roundtable discussions, abstracts, and workshops on spirometer, patient/physician education materials, and home monitoring/telemetry. The goal was to bring together a multidisciplinary group to identify important issues relating to COPD in the United States, and across the world.  Specifically the barriers to a wider recognition of the disease, and to develop an orchestrated action plan. Over 500 scientists, clinicians, respiratory therapists, nurses, patients, government officials, and representatives from pharmaceutical companies   will be participated. This summary provides the recommendations from the conference that will be used to develop an action plan for the US COPD Coalition. It includes actions proposed by plenary speakers, roundtable faculty and conference participants.

Importance & Scope:

Evidence continues to mount the present study suggest that   the manner in which COPD   patients evaluate their perception of difficulty   and the importance of physical tasks. Owing to its major and better recognised burden from both individual and societal perspectives, chronic obstructive pulmonary disease (COPD) is an area of intensive epidemiological, fundamental and clinical research, leading to the publication of more than 10,000 papers each year. Among these, many report important advances in the understanding of and care for COPD It is recommended that future research and intervention efforts aims at maximizing the quality of life of terminally ill patients continue to examine the factors that influence patient’s perception of their physical function .This event aims at perfect opportunity for the people across the globe to widen their knowledge.

Why Brisbane?

One of the oldest cities in Australia, Brisbane was founded upon the ancient homelands of the Turrbal and Jagera peoples. Brisbane has seen consistent economic growth in recent years as a result of the resources boom. White-collar industries include information technology, financial services, higher education and public sector administration generally concentrated in and around the central business district and recently established office areas in the inner suburbs. Blue-collar industries, including petroleum refining, stevedoring, paper milling, metal working and QR railway workshops, tend to be located on the lower reaches of the Brisbane River and in new industrial zones on the urban fringe. There are many health centers, rehabilitation centers which are associated with pulmonary function studies, including body plethysmography, gas transfer measurement, exercise testing, measurement of chemical drives to ventilation and bronchial reactivity.

Conference Highlights:

Lungs and its Functions; An Overview

Causes of COPD

Pathophysiology of COPD

COPD and Co-Morbidities

Drugs Acting on COPD

Clinical Evaluation of COPD

Diagnostic Techniques of COPD

Developments in COPD Management

Advancement in Lung Surgeries

Control Measures for Prevention of COPD

Members Associated with COPD Research

The COPD-2016 will  put together a scientific programme in the form of scientific symposia, plenary lectures, interactive sessions and workshops covering Clinical and Respiratory Medicine, , Clinical Allergy , Environmental and Occupational Health and Epidemiology, Respiratory Infections, Tuberculosis, Asthma, Chronic Obstructive Lung Disease, Lung Cancer , Critical Care Medicine, Bronchoscopy and Interventional Techniques, Paediatric Lung Disease, Respiratory Structure and Function. . The members associated with the copd research are International Primary Care Respiratory Group (IPRCRG), Dutch Lung Alliance (LAN), LoveXAir, Pfizer, GlaxoSmithKline (GSK) Boehringer Ingelheim and Novartis.

Hospitals Associated with   COPD Research

Hospitals on COPD research defines premium rebates allocated to medical services, Medicare co-payments and other out-of-pocket payments. Also includes non-MBS medical services, such as the provision of vaccines for overseas travel, as well as some expenditure under funding arrangements that are alternatives to the fees for service.  This accounted for 1.3% of the total direct expenditure on diseases.

COPD expenditure consisted of:

57% admitted patient costs

 23% prescription medicines

 19% out-of-hospital medical services.

 Includes public and private acute hospitals, and psychiatric hospitals. Includes medical services provided to private admitted patients in hospital.

Hospitals associated on COPD research are

Henry Ford Hospital,   United States

Royal Brompton & Hare field, London, United Kingdom

Alfred   Hospital, Melbourne, Australia

Wesley Medical Centre Wichita, United States

Sydney Interventional Pulmonology    Sydney, Australia

Macquarie University Hospital, Australia

Includes all pharmaceuticals that are listed in the schedule under the Pharmaceutical Benefits Scheme (PBS) and the Repatriation Pharmaceutical Benefits Scheme (RPBS) for which pharmaceutical benefits have been paid or are payable. Also includes costs for under co-payment and private prescriptions.

Major COPD Research Associations Around The Globe

Ontario Lung Association

American lung association

British Thoracic Society

COPD thoracic society

Canadian thoracic society

Irish thoracic societ

American thoracic society

American college of chest physicians chest journal

COPD –alert support and advocacy group

COPD –international

Emphysema foundation for our right to survive

The global initiative for chronic obstructive lung disease

National lung health education program

Pulmonary education &research foundation

European respiratory society

Asthma Society of Canada

Australian lung foundation

Pulmonary fibrosis foundation

Pulmonary fibrosis UK

National heart, lung and blood institute , national institutes of health

Pulmonary hypertension association

 

COPD Research Associations in Region Wise (Percentage)

Top Universities On COPD Research

       Australian national university ,  Australia

 University of Queenslandon   Queensland, Australia

 Macquarie University, Australia

University of Tasmania – Tasmania   Australia

Charles Darwin University Casoria Australia

University-of-the-sunshine-coast    Brisbane, Australia

Curtin University Bentley, Australia

Murdoch University   Murdoch, Australia

University of Canberra      Bruce, Australia

University of Maastricht      Netherlands, Europe

Tufts university ranking   Medford, ‎, United States

McGill university   Montréal, Canada

University Of Maryland Medical  Center  ,United States

Columbia University Medical  Center  , United States

University Of Maryland Medical Center  ,Australia

University Of  Melbourne  ,Australia

University Of Minnesota  , United States

 University Of British Columbia ,Canada

University Of Chicago Medicine  , United States

University Of Buffalo  , United States

University Of London Imperial College Of Science Technology And Medicine ,United Kingdom

Harvard University, , United States

Johns Hopkins University  , United States

University  Of Pittsburgh , United States

University  Of  Colorado  , United States

University  Of California Los Angeles  , United States

University Of  Toronto  , Canada

University Of Colorado , United States

University Of Washington   , United States

Imperial College London  ,United Kingdom

University Of Groningen  , Netherlands

Universities Associated With COPD Research in Region Wise

Companies Associated With COPD Research

AstraZeneca,

   Switzerland, Europe

Bayer

   Germany, Europe

Boehringer Ingelheim,

      Germany, Europe

Chiesi Pharmaceutical

     Italy, Europe

Forest Laboratories

    New York, united states

Lallemand Pharma

     Switzerland, Europe

Merck & Co

    New Jersey,   United States

Novartis

  Switzerland, Europe

Sunovion Pharmaceuticals

    Massachusetts, United States

Gsk

    Brentford, London

Almirall

     Barcelona, Spain

Queensland Respiratory Laboratory Pty. Ltd.

   Queensland, Australia

Pharma Company Revenue in Billions

 

Funding Associations

12 million US adults are diagnosed with COPD. CDC estimates that another 12 million have disease and it costs the economy almost $ billion a year, including$ 29 billion in direct medical cost

CHEST Foundation Research Grant in Chronic Obstructive Pulmonary Disease $50,000 1-year grant

In Europe 6.3 million funds are releasing per year in order to diagnosis and treatment analysis

CDC estimates that 50 to 80 million people are suffering with the disease.

Market Research

The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019. Much of this growth will be fuelled by a high number of new, more efficacious and convenient products entering the market particularly in USA Europe, Middle East and Asia specific and commanding greater value compared to the therapies already in the market.

Between 3 and 7 million Americans are currently diagnosed with chronic obstructive pulmonary disease (COPD), and the true prevalence is probably greater than 16 million (1). Many of these individuals suffer years of progressive discomfort and disability. With the number of deaths per year attributed to this disease at approximately 100,000 and increasing, COPD is now the fourth leading cause of death in this country (2) and is expected to be third by the year 2020. Better means are clearly needed for the prevention and treatment of COPD,

This report updates surveillance results for COPD throughout the world. From 1999 to 2011, the overall age-adjusted prevalence of having been diagnosed with COPD declined in 2011, 6.5% of adults (approximately 13.7 million) reported having been diagnosed with COPD. The global Europe  market COPD and asthma devices market would reach $34.3 billion by 2020, registering a CAGR of 4.5% during 2014 - 2020. Considering the growth and market size, Dry Powder Inhalers (DPIs) will be the most lucrative market segment of the COPD and Asthma devices (inhalers) market by 2020.

Projection Rate on COPD

The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018.

By 2018, it is expected that the combinations of LABA/LAMA would the leading drugs driving sales in the COPD therapy market and by 2021, these drugs would account for more than 25% of the market share. While in 2013, close to 50% of the global market was accounted by the US, with the other regions together accounting for 50%. However, it is expected that by 2018, the share of the USA would reduce marginally to 45%, while the lost share of this region would be taken over by the Asian region.

Many of the elderly who are affected have other chronic and often disabling conditions, and the number of elderly affected is expected to rise. COPD is currently the fourth leading cause of death in the United States. And is forecasted to rank fifth worldwide in disease burden by the year 2020. 

 

References:

https://www.fphcare.com/files/ investor-fact-sheet/

http://en.wikipedia.org/Wiki/rankings_of_universities

http://en.wikipedia.org/wiki/List of pharmaceutical companies

http://www.grandviewresearch.com/industry-analysis/copd market

http://www.marketresearchreports.bix/tag/COPD

http://en.wikipedia.org/wiki/brisbane

http://www.ncbi.nih.gov/pubmed

 

 

 

 

 

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date July 11-12, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2
Poster Opportunity Closed Click Here to View

Media Partners